SCH Investment Partners LLC filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 150,000 Class A Ordinary Shares of Royalty Pharma PLC on NASDAQ:RPRX through Merrill Lynch.
Key Highlights
- Proposed sale: SCH Investment Partners LLC intends to sell 150,000 Class A Ordinary Shares with an aggregate market value of $10,176,000.
- Shares acquired: The 150,000 shares were acquired on May 13, 2024, from the issuer in a private transaction at no cash cost listed (payment nature listed as N/A).
- Approximate sale date: The filing lists November 17, 2026 as the approximate date of sale, to be executed through Merrill Lynch in New York.
- 10b5-1 plan: According to the filing, the sales are made under a selling plan dated March 20, 2026, intended to comply with Rule 10b5-1(c).
- Prior sales in past three months: SCH Investment Partners LLC sold 100,000 shares on September 22, 2026 for gross proceeds of $5,846,972.43, and 100,000 shares on August 18, 2026 for gross proceeds of $5,991,122.91.
- Shares outstanding: The filing reports 445,265,805 Class A Ordinary Shares outstanding.
- Relationship to issuer: The filing identifies SCH Investment Partners LLC as an officer of Royalty Pharma PLC, and the notice was signed by Christopher Hite.
SCH Investment Partners LLC Proposes Sale Under 10b5-1 Plan at Royalty Pharma
According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 17, 2026, SCH Investment Partners LLC, identified as an officer-affiliated entity of Royalty Pharma PLC (NASDAQ:RPRX), proposes to sell 150,000 Class A Ordinary Shares. The filing states the aggregate market value of the proposed sale is $10,176,000, with the transaction to be executed through Merrill Lynch at One Bryant Park, New York, NY 10036.
The filing discloses that the 150,000 shares slated for sale were acquired on May 13, 2024, through a private transaction directly from the issuer. The notice states that the nature of payment was listed as N/A. The proposed sale is linked to "a selling plan dated 03/20/2026, which is intended to comply with Rule 10b5-1(c)," according to the remarks section of the filing.
The filing also details prior sales by SCH Investment Partners LLC over the past three months. The entity sold 100,000 shares on September 22, 2026 for gross proceeds of $5,846,972.43 and an additional 100,000 shares on August 18, 2026 for gross proceeds of $5,991,122.91, both transactions involving Royalty Pharma Class A Ordinary Shares. The notice was signed by Christopher Hite and bears a notice date of November 17, 2026.
What Was Disclosed
SCH Investment Partners LLC filed a Form 144 notice proposing the sale of 150,000 Royalty Pharma Class A Ordinary Shares valued at $10,176,000, under a 10b5-1 plan adopted March 20, 2026, with the sale expected on or around November 17, 2026.




Please wait processing your request...